Evidence map›Paper›PMID 39043465›Full record

ArticleBMJ mental health2024

Parkinson's disease psychosis associated with accelerated multidomain cognitive decline.

Sara Pisani, Luca Gosse, Dag Aarsland, K Ray Chaudhuri, Clive Ballard, Dominic Ffytche, Latha Velayudhan, Sagnik Bhattacharyya

Registry-linked trialAbstract read
In one paragraph

Article in BMJ mental health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01141023 (The Parkinson's Progression Markers Initiative), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01141023 phase2completednot on this map

The Parkinson's Progression Markers Initiative (PPMI)

TypeinterventionalSponsorKen Marek, MDRan2010 to 2020Enrolled952ConditionsParkinson DiseaseArmsDaTscan
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Update on sleep disorders in advanced Parkinson's disease: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara PisaniDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0001-8532-4650
Luca GosseFaculty of Medicine, Dentistry and Health, The University of Sheffield, Sheffield, UK.
Dag AarslandDepartment of Psychological Medicine, Centre for Healthy Brain Ageing, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
K Ray ChaudhuriNational Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, London, UK.
Clive BallardFaculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Dominic FfytcheDepartment of Psychological Medicine, Centre for Healthy Brain Ageing, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0002-4214-9642
Latha VelayudhanDepartment of Psychological Medicine, Centre for Healthy Brain Ageing, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Sagnik BhattacharyyaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK sagnik.2.bhattacharyya@kcl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive deficits are associated with poor quality of life and increased risk of development of dementia in patients with Parkinson's disease (PD) psychosis. The trajectory of cognitive decline in PD psychosis remains however unclear.

objectiveWe examined this using data from the Parkinson's Progression Markers Initiative study.

methodsWe analysed data from patients with drug-naïve PD (n=676) and healthy controls (HC, n=187) over 5 years, and examined all cognitive measures assessed at each time point. We classified patients with PD into those who developed psychosis over the course of the study (PDP) and those without psychosis throughout (PDnP) using the Movement Disorders Society Unified Parkinson's Disease Rating Scale part I hallucinations/psychosis item. We used linear mixed-effect models with restricted maximum likelihood. Age, sex, ethnicity, education and neuropsychiatric and PD-specific symptoms were entered as covariates of interest.

findingsThere were no baseline cognitive differences between PD patient groups. There were differences in cognitive performance between PD and HC across the majority of the assessments.Patients with PDP exhibited greater cognitive decline over 5 years compared with PDnP across most domains even after controlling for sociodemographics, depression, sleepiness, rapid eye movement sleep behaviour disorder and motor symptom severity (immediate recall, b=-0.288, p

conclusionsPatients with PD psychosis exhibited decline in semantic aspects of language, processing speed, global cognition, visuospatial abilities and memory, regardless of sociodemographic characteristics, neuropsychiatric and motor symptoms. These cognitive domains, particularly semantic aspects of language may therefore play an important role in PD psychosis and warrant further investigation. TRIAL REGISTRATION NUMBER: NCT01141023.

Indexed as

Cognitive DysfunctionParkinson DiseasePsychotic DisordersAgedDisease ProgressionFemaleHumansMaleMiddle AgedNeuropsychological Testspsychiatry

Identifiers

PMID39043465
PMCPMC11268075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.